Vivozon Pharmaceutical Co., Ltd. (KOSDAQ: 082800)
South Korea flag South Korea · Delayed Price · Currency is KRW
6,090.00
-10.00 (-0.16%)
Nov 18, 2024, 12:43 PM KST

Vivozon Pharmaceutical Income Statement

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 2018 - 2014
Period Ending
Jun '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 2018 - 2014
Operating Revenue
81,51871,31851,56457,56043,59243,974
Upgrade
Other Revenue
0---0-978.75
Upgrade
Revenue
81,51871,31851,56457,56043,59244,953
Upgrade
Revenue Growth (YoY)
37.23%38.31%-10.42%32.04%-3.03%-2.28%
Upgrade
Cost of Revenue
42,63039,99730,12837,92136,46141,654
Upgrade
Gross Profit
38,88931,32121,43719,6397,1303,299
Upgrade
Selling, General & Admin
30,19325,08223,03128,62710,4274,038
Upgrade
Research & Development
3,2062,5411,9273,9352,870380.5
Upgrade
Operating Expenses
34,47226,61131,24339,25315,1696,088
Upgrade
Operating Income
4,4164,709-9,806-19,615-8,039-2,789
Upgrade
Interest Expense
-2,249-2,904-5,271-7,297-10,792-7,560
Upgrade
Interest & Investment Income
193.64345.14840.79909.591,274432.33
Upgrade
Earnings From Equity Investments
----691.35-963.27
Upgrade
Currency Exchange Gain (Loss)
-63.41-6.07125.03999.14-774.58203.4
Upgrade
Other Non Operating Income (Expenses)
-380.65-43.59-940-402.961,78217.53
Upgrade
EBT Excluding Unusual Items
1,9172,101-15,051-26,097-16,549-8,733
Upgrade
Gain (Loss) on Sale of Investments
-3,887-3,633-4,84269.4-3,621-9,279
Upgrade
Gain (Loss) on Sale of Assets
-669.66-596.57-102.92-229.9337.98-2,156
Upgrade
Asset Writedown
-29.21-29.21-5,252-49,590-23,990-2,472
Upgrade
Other Unusual Items
---92.74---
Upgrade
Pretax Income
-2,669-2,158-25,342-75,848-43,822-22,639
Upgrade
Income Tax Expense
55.2755.271,509-4,833263.27-
Upgrade
Earnings From Continuing Operations
-2,725-2,214-26,851-71,015-44,085-22,639
Upgrade
Earnings From Discontinued Operations
16.59-1,143-13,827---6,368
Upgrade
Net Income to Company
-2,708-3,357-40,677-71,015-44,085-29,006
Upgrade
Minority Interest in Earnings
--771.551,558330.61,008
Upgrade
Net Income
-2,708-3,357-39,906-69,457-43,754-27,998
Upgrade
Net Income to Common
-2,708-3,357-39,906-69,457-43,754-27,998
Upgrade
Shares Outstanding (Basic)
474844332621
Upgrade
Shares Outstanding (Diluted)
474844332621
Upgrade
Shares Change (YoY)
0.13%9.69%33.41%24.52%24.63%65.66%
Upgrade
EPS (Basic)
-57.06-70.35-917.27-2129.90-1670.65-1332.34
Upgrade
EPS (Diluted)
-57.06-70.35-917.27-2130.00-1670.65-1332.34
Upgrade
Free Cash Flow
-2,817-1,532-9,814-27,6083,755-4,106
Upgrade
Free Cash Flow Per Share
-59.36-32.10-225.59-846.59143.39-195.38
Upgrade
Gross Margin
47.71%43.92%41.57%34.12%16.36%7.34%
Upgrade
Operating Margin
5.42%6.60%-19.02%-34.08%-18.44%-6.20%
Upgrade
Profit Margin
-3.32%-4.71%-77.39%-120.67%-100.37%-62.28%
Upgrade
Free Cash Flow Margin
-3.46%-2.15%-19.03%-47.96%8.62%-9.13%
Upgrade
EBITDA
7,8187,937-6,162-14,062-5,860-672.11
Upgrade
EBITDA Margin
9.59%11.13%-11.95%-24.43%-13.44%-1.50%
Upgrade
D&A For EBITDA
3,4013,2283,6435,5522,1792,117
Upgrade
EBIT
4,4164,709-9,806-19,615-8,039-2,789
Upgrade
EBIT Margin
5.42%6.60%-19.02%-34.08%-18.44%-6.20%
Upgrade
Advertising Expenses
-617.321,6884,4191,0373.3
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.